| Literature DB >> 32013668 |
Marie-Christine Klein1, Monika Lerner1, Duy Nguyen2, Stefan Pfeffer3, Johanna Dudek1, Friedrich Förster4, Volkhard Helms2, Sven Lang1, Richard Zimmermann1.
Abstract
In <span class="Species">mammalian cells, one-third of all poly<span class="Chemical">peptides is transported into or through the ER-membrane via the Sec61-channel. While the Sec61-complex facilitates the transport of all polypeptides with amino-terminal signal peptides (SP) or SP-equivalent transmembrane helices (TMH), the translocating chain-associated membrane protein (now termed TRAM1) was proposed to support transport of a subset of precursors. To identify possible determinants of TRAM1 substrate specificity, we systematically identified TRAM1-dependent precursors by analyzing cellular protein abundance changes upon TRAM1 depletion in HeLa cells using quantitative label-free proteomics. In contrast to previous analysis after TRAP depletion, SP and TMH analysis of TRAM1 clients did not reveal any distinguishing features that could explain its putative substrate specificity. To further address the TRAM1 mechanism, live-cell calcium imaging was carried out after TRAM1 depletion in HeLa cells. In additional contrast to previous analysis after TRAP depletion, TRAM1 depletion did not affect calcium leakage from the ER. Thus, TRAM1 does not appear to act as SP- or TMH-receptor on the ER-membrane's cytosolic face and does not appear to affect the open probability of the Sec61-channel. It may rather play a supportive role in protein transport, such as making the phospholipid bilayer conducive for accepting SP and TMH in the vicinity of the lateral gate of the Sec61-channel.Abbreviations: ER, endoplasmic reticulum; OST, oligosaccharyltransferase; RAMP, ribosome-associated membrane protein; SP, signal peptide; SR, SRP-receptor; SRP, signal recognition particle; TMH, signal peptide-equivalent transmembrane helix; TRAM, translocating chain-associated membrane protein; TRAP, translocon-associated protein.Entities:
Keywords: Endoplasmic reticulum; protein transport; translocating chain-associated membrane protein
Mesh:
Substances:
Year: 2020 PMID: 32013668 PMCID: PMC7039644 DOI: 10.1080/19336950.2020.1724759
Source DB: PubMed Journal: Channels (Austin) ISSN: 1933-6950 Impact factor: 2.581
Figure 1.Putative position of TRAM1 in the ER membrane and experimental strategy for the identification of TRAM1 clients and compensatory proteins by TRAM1 depletion in HeLa cells.
(a) 3D structure of the native ER-associated 80S ribosome together with Sec61-complex (not visible due to the absence of soluble domains of relevant size), TRAP-complex (red ER luminal density), and OST (red ER luminal density) [20], both identified by siRNA-mediated depletion from HeLa cells and subsequent CET, as well as a non-ribosomal density (shown in red at the interface of the two ribosomal subunits) that potentially corresponds to canonical translation elongation or termination factors. (b) Spatial organization of OST, Sec61 (with transmembrane domains), and TRAP in the translocon as seen from the ER lumen. For TRAP and OST, membrane anchors (TM regions) and lumenal segments (pink lines) from the native translocon, as well as TM density from the solubilized translocon, were projected onto the membrane plane. The ribosomal tunnel exit for nascent polypeptide chains (red dot labeled peptide exit) and the putative position of TRAM1 opposite of the lateral gate of the Sec61-channel are indicated, together with additional not-annotated electron densities in the plane of the membrane. (c) The experimental strategy was as follows: siRNA-mediated gene silencing using two different siRNAs for the target and one non-targeting (control) siRNA, respectively, with six replicates for each siRNA in two independent experiments; label-free quantitative proteomic analysis; and differential protein abundance analysis to identify negatively affected proteins (i.e. clients) and positively affected proteins (i.e. compensatory proteins).
Figure 2.Amino acid sequences of TRAM1, TRAM1L1, and TRAM2.
The sequences and positions of transmembrane (TM, black bar) domains 1 through 8 of TRAM1, TRAM1L1, and TRAM2 were retrieved from UniProtKB and aligned using the Megalign option of the DNASTAR software package (Lasergene 12). Using the same software, we determined sequence identities of 71% for TRAM1 and TRAM1L1, 50% for TRAM and TRAM2, and 42% for TRAM2 and TRAM1L1. Conserved aromatic residues in transmembrane domains are highlighted in red and given in single letter code. Since the TRAM1 antibodies were raised against the carboxy-terminal dodecapeptide, they are not expected to cross-react with TRAM1L1 and TRAM2.
Statistics of the identification of TRAM1 clients in comparison to the identification of Sec61α1 and TRAP clients, respectively.
| Proteins | SEC61A1 | TRAM1 | TRAP |
|---|---|---|---|
| Quantified proteins | 7212 | 7502 | 7670 |
| Statistically analyzed proteins | 5129 | 5961 | 5911 |
| representing the secretory pathway (%) | 26 | 28 | 27 |
| Proteins with SP (%) | 6 | 7 | 7 |
| N-Glycoproteins (%) | 8 | 9 | 8 |
| Membrane proteins (%) | 12 | 14 | 13 |
| Positively affected proteins | 342 | 118 | 77 |
| Negatively affected proteins | 482 | 86 | 180 |
| representing the secretory pathway (%) | 61 | 48 | 40 |
| Negatively affected proteins with SP (%) | 41 | 16 | 22 |
| Negatively affected N-glycoproteins (%) | 45 | 21 | 23 |
| Negatively affected membrane proteins (%) | 36 | 24 | 26 |
| Negatively affected proteins with SP | 197 | 13 | 38 |
| Including N-glycoproteins | 158 | 7 | 28 |
| Corresponding to % | 80 | 54 | 74 |
| Including membrane proteins | 77 | 4 | 19 |
| Corresponding to % | 39 | 31 | 50 |
| Negatively affected proteins with TMH | 98 | 17 | 22 |
| Including N-glycoproteins | 56 | 9 | 11 |
| Corresponding to % | 57 | 53 | 50 |
Figure 3.Identification of TRAM1 clients and compensatory proteins by TRAM1 depletion in HeLa cells.
To identify TRAM1 clients, siRNA-mediated gene silencing was performed in HeLa cells for 96 h using two different siRNAs for the target (TRAM1 #2-UTR siRNA, TRAM1 #6-UTR siRNA) and one non-targeting (control) siRNA (AllStars Negative Control siRNA), respectively, with a total of six replicates for each siRNA in two independent experiments. As previously established [38], label-free quantitative proteomic analysis and differential protein abundance analysis were employed to identify negatively affected proteins (i.e. clients) and positively affected proteins (i.e. compensatory proteins). (a) Differentially affected proteins were characterized by the mean difference of their intensities plotted against the respective permutation false discovery rate-adjusted p-values in volcano plots (n = 2). The results for the two siRNA for the target (TRAM1 #2-UTR siRNA, left plot; TRAM1 #6-UTR siRNA, right plot) are shown separately. (b) Knock-down efficiencies were evaluated by western blot. Results from one experiment are presented as % of residual protein levels (normalized to ß-actin) relative to control, which was not affected by TRAM1 depletion (Supplementary Table 1) and set to 100%. (c) Protein annotations of signal peptides, membrane location, and N-glycosylation in humans were extracted from UniProtKB and used to determine the enrichment of Gene Ontology annotations among the secondarily affected proteins. Summaries of the two TRAM1 depletion experiments are shown. We note that enrichment factors were calculated by dividing the indicated percent values for the negatively affected proteome by the corresponding value for the total quantified proteome. (d) Venn diagram for the overlap of precursor polypeptides with SP or TMH between TRAM1 and TRAP clients [38]. Details are given in Table 2.
Summary of TRAM1 clients and their characteristics in comparison to Sec61α1 and TRAP clients, respectively. Protein abundances in HeLa cells are given in nM and were taken from Hein et al., 2015 [74]. N-glyco, number of N-glycosylation sites; nd, not detected; TMD, number of transmembrane domains, including TMH where applicable.
| SEC61A1 | TRAM1 | TRAP | SP/TMH | TMD | N-glyco | nM |
|---|---|---|---|---|---|---|
| ADAM10 | ADAM10 | ADAM10 | SP | 1 | 4 | 60 |
| BMP1 | BMP1 | SP | 0 | 5 | 5 | |
| BNIP3L | nd | TMH | 1 | 0 | 5 | |
| CLCC1 | SP | 3 | 0 | 91 | ||
| CLN5 | CLN5 | TMH | 1 | 8 | nd | |
| CNPY4 | CNPY4 | CNPY4 | SP | 0 | 0 | 123 |
| CTSB | CTSB | SP | 0 | 1 | 198 | |
| nd | CYR61 | CYR61 | SP | 0 | 0 | nd |
| nd | DEGS1 | DEGS1 | TMH | 6 | 0 | 275 |
| nd | DNAJC25 | nd | SP | 0 | 0 | 10 |
| ERLIN2 | ERLIN2 | TMH | 1 | 1 | 492 | |
| ERO1L | ERO1L | SP | 0 | 2 | 510 | |
| GALNT3 | GALNT3 | TMH | 1 | 3 | nd | |
| GGH | GGH | SP | 0 | 4 | 42 | |
| GLIPR1 | SP | 1 | 0 | 3 | ||
| ITPRIP | ITPRIP | SP | 0 | 2 | 18 | |
| nd | JPH1 | nd | TMH | 1 | 0 | 18 |
| KCNN4 | TMH | 6 | 0 | 1 | ||
| LNPEP | LNPEP | LNPEP | TMH | 1 | 17 | 63 |
| MTDH | MTDH | TMH | 1 | 0 | 575 | |
| NEU1 | NEU1 | NEU1 | TMH | 0 | 3 | 5 |
| P4HTM | P4HTM | TMH | 1 | 3 | 5 | |
| PLD3 | PLD3 | TMH | 1 | 2 | 82 | |
| PLP2 | TMH | 4 | 2 | 35 | ||
| SEC11A | SEC11A | TMH | 1 | 0 | 97 | |
| SPPL2A | SP | 9 | 7 | 7 | ||
| STEAP2 | STEAP2 | nd | TMH | 6 | 2 | nd |
| nd | TMEM223 | TMEM223 | TMH | 2 | 0 | 21 |
| TOR4A | TOR4A | nd | TMH | 1 | 0 | 4 |
| UGGT2 | UGGT2 | SP | 0 | 4 | 3 |
Figure 5.TRAM1 depletion plus live-cell Ca2+ imaging does not reveal a TRAM1 function in the Sec61-channel opening.
(a–h) HeLa cells were treated with two different siRNAs for the target (TRAM1 #2-UTR siRNA, TRAM1 #6-UTR siRNA) and one non-targeting (control, ctr) siRNA for 96 h, loaded with Fura 2, and subjected to live-cell imaging of cytosolic Ca2+ following our established procedure [38,57–60]. Ca2+ release was unmasked by the addition of thapsigargin (Tg) (a and e) or Ionomycin (Iono) (b and f) in the presence of external EGTA. Typically, data were collected in three independent experiments with triplicate cultures for each condition. Average values are presented with the standard error of the mean (s.e.m.), with n referring to the number of cells. The statistical analysis of the changes in cytosolic Ca2+ after thapsigargin and ionomycin addition, respectively, is shown in c, d, g, and h (mean values with s.e.m.: n is indicated and refers to the number of culture dishes). P-values were calculated by unpaired t-test on the basis of standard deviations (n.s., not significant). The effects of siRNA-mediated depletion of TRAP are indicated for comparison as red lines [38]. (i, j) Knock-down efficiency was evaluated for various TRAM1-targeting siRNAs by western blots. A representative western blot is shown in J. The silencing statistics for the relevant siRNAs #2 and #6 are shown in I (mean values with s.e.m.; n = 7 for #2; n = 4 for #6). Results are presented as % of residual TRAM1 levels (normalized to ß-actin) relative to control, which was set to 100%.
Figure 4.Physico-chemical properties of TRAM1 clients with SP and TMH.
We used custom scripts to compute the hydrophobicity score (a, d) and glycine/proline (GP) content (c, f) of SP (a–c) and TMH (d–f) sequences of TRAM1 clients (red lines, TRAM). Hydrophobicity score was calculated as the averaged hydrophobicity of its amino acids according to the well-known Kyte–Doolittle propensity scale [72]. GP content was calculated as the total fraction of glycine and proline in the respective sequence. (b, e). ∆Gapp values of SP and TMH were calculated with the ∆Gapp predictor for TM helix insertion (http://dgpred.cbr.su.se). The same calculations were applied for all human SP (human). Wilcoxon rank test p values are indicated.